GRAIL Reports Mixed NHS-Galleri Trial Results and Announces U.S. Sales Force Expansion

GRAIL, Inc. (Nasdaq: GRAL) has released topline results from its massive NHS-Galleri trial, which involved 142,000 participants in England. While the study failed to meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses, it demonstrated a favorable overall trend. Notably, the trial showed a substantial reduction in Stage IV diagnoses and a four-fold increase in the cancer detection rate compared to the control group. These results, alongside the PATHFINDER 2 study, have prompted GRAIL to initiate a strategic expansion of its sales force in the United States. The company remains focused on the commercial viability of its multi-cancer early detection technology despite the mixed clinical outcome. Investors are currently weighing the missed primary goal against the significant improvements in late-stage detection and the company's aggressive commercial push.